Pettinga Financial Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Pettinga Financial Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,275	Closed	-$202K	–	171
2026 Q2	$202K	Sell	1,275 -3,886	-75%	-$525K	0.03%	148
2026 Q1	$659K	Sell	5,161 -9,355	-64%	-$1.17M	0.12%	91
2025 Q4	$1.77M	Sell	14,516 -4,024	-22%	-$461K	0.34%	52
2025 Q3	$1.86M	Buy	18,540 +795	+4%	+$71.6K	0.36%	51
2025 Q2	$1.47M	Sell	17,745 -10,915	-38%	-$871K	0.32%	50
2025 Q1	$2.32M	Sell	28,660 -245	-0.8%	-$21.9K	0.55%	43
2024 Q4	$2.6M	Buy	28,905 +3,297	+13%	+$319K	0.59%	40
2024 Q3	$2.53M	Sell	25,608 -1,025	-4%	-$101K	0.6%	35
2024 Q2	$2.47M	Buy	26,633 +193	+0.7%	+$17.3K	0.62%	36
2024 Q1	$2.51M	Sell	26,440 -405	-2%	-$37.6K	0.64%	38
2023 Q4	$2.4M	Buy	26,845 +8,030	+43%	+$596K	0.64%	39
2023 Q3	$1.37M	Buy	18,815 +475	+3%	+$37.9K	0.42%	40
2023 Q2	$1.53M	Sell	18,340 -870	-5%	-$72.8K	0.45%	38
2023 Q1	$1.46M	Buy	19,210 +960	+5%	+$79.7K	0.46%	38
2022 Q4	$1.51M	Sell	18,250 -2,020	-10%	-$164K	0.49%	39
2022 Q3	$1.61M	Buy	20,270 +3,295	+19%	+$278K	0.55%	37
2022 Q2	$1.26M	Buy	16,975 +4,525	+36%	+$340K	0.38%	45
2022 Q1	$1.12M	Buy	12,450 +1,985	+19%	+$183K	0.28%	52
2021 Q4	$1.17M	Buy	10,465 +4,823	+85%	+$582K	0.28%	54
2021 Q3	$709K	Buy	+5,642	New	+$727K	0.18%	61
2020 Q2	–	Sell	-7,070	Closed	-$548K	–	85
2020 Q1	$548K	Buy	+7,070	New	+$626K	0.37%	40
2019 Q4	–	Sell	-13,875	Closed	-$1.06M	–	93
2019 Q3	$1.06M	Buy	13,875 +10,325	+291%	+$858K	0.57%	37
2019 Q2	$311K	Buy	+3,550	New	+$303K	0.16%	75
2019 Q1	–	Sell	-9,000	Closed	-$646K	–	102
2018 Q4	$646K	Buy	+9,000	New	+$725K	0.42%	37

Other funds holding XBI

MIRAE ASSET SECURITIES (USA) INC. New York $3.57B AUM 26.78% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return

EWM

Edge Wealth Management New York $666M AUM 17.64% 1-Year Est. Return

LHWM

Lake Hills Wealth Management Austin, Texas $218M AUM 31.66% 1-Year Est. Return

AIC

Ayalon Insurance Company Ramat Gan, Israel $1.2B AUM 25.57% 1-Year Est. Return

MWA

MFA Wealth Advisors Pittsburgh, Pennsylvania $589M AUM 19.71% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Fiduciary Alliance Greenville, South Carolina $1.33B AUM 15.58% 1-Year Est. Return

MAM

Marotta Asset Management Charlottesville, Virginia $589M AUM 14.57% 1-Year Est. Return

Fulcrum Capital Seattle, Washington $525M AUM 23.04% 1-Year Est. Return

Pettinga Financial Advisors's XBI Position: Q3 2026 in Review

Pettinga Financial Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2026, closing a stake of 1,275 shares — an estimated $202K sold.

Pettinga Financial Advisors first reported a position in XBI in Q4 2018 and held it in 24 quarters. The position peaked at $2.6M in Q4 2024. 115 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Pettinga Financial Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2026 after selling out during the quarter.
Pettinga Financial Advisors sold 1,275 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $202K.
Pettinga Financial Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and held it in 24 quarters.
Pettinga Financial Advisors's State Street SPDR S&P Biotech ETF position peaked at $2.6M in Q4 2024.
115 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Pettinga Financial Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.